Drug Trial Radar · NCT06182358
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Dec 27, 2023
Primary completion
Jan 27, 2025
Study completion Jan 27, 2025
Sponsor
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
Conditions
- Demodex Blepharitis
Interventions
Lotilaner ophthalmic solution, 0.25%Drug
XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
Vehicle controlDrug
Vehicle of XDEMVY administered topically twice a day for approximately 43 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of collarettes at Day 43Time frame: 43 days
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Site
Cave Creek, Arizona
Site
Long Beach, California
Vision Institute
Colorado Springs, Colorado
Site
Delray Beach, Florida
Site
Indianapolis, Indiana
Site
Pittsburg, Kansas
Site
Louisville, Kentucky
Site
Edina, Minnesota
Site
Shelby, North Carolina
Site
Fargo, North Dakota
Site
Powell, Ohio
Site
Cranberry Township, Pennsylvania
Site
Memphis, Tennessee
Site
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.